A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods-Reference-Cited by-同舟云学术

A Step toward NRF2‐DNA Interaction Inhibitors by Fragment‐Based NMR Methods

Published:2021-10-08 Issue:23 Volume:16 Page:3576-3587
ISSN:1860-7179
Container-title:ChemMedChem
language:en
Short-container-title:ChemMedChem

Author:

Brüschweiler Sven¹^ORCID,Fuchs Julian E.²^ORCID,Bader Gerd²^ORCID,McConnell Darryl B.²^ORCID,Konrat Robert¹^ORCID,Mayer Moriz²^ORCID

Affiliation:

1. Christian Doppler Laboratory for High-Content Structural Biology and Biotechnology Department of Structural and Computational Biology, Max Perutz Labs University of Vienna Campus Vienna Biocenter 5 1030 Vienna Austria

2. Boehringer Ingelheim RCV GmbH & Co. KG Dr. Boehringer Gasse 5–11 1121 Vienna Austria

Funder

Österreichische Nationalstiftung für Forschung, Technologie und Entwicklung

Christian Doppler Forschungsgesellschaft

Publisher

Wiley

Subject

Organic Chemistry,General Pharmacology, Toxicology and Pharmaceutics,Molecular Medicine,Drug Discovery,Biochemistry,Pharmacology

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cmdc.202100458

Reference84 articles.

1. Modulating NRF2 in Disease: Timing Is Everything

3. Comprehensive genomic characterization of squamous cell lung cancers

4. Potential Applications of NRF2 Inhibitors in Cancer Therapy

5. Distinct patterns of somatic genome alterations in lung adenocarcinomas and squamous cell carcinomas

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Ligandability assessment of the C‐terminal Rel‐homology domain of NFAT1;Archiv der Pharmazie;2024-02-23

2. The current status and future prospects for therapeutic targeting of KEAP1-NRF2 and β-TrCP-NRF2 interactions in cancer chemoresistance;Free Radical Biology and Medicine;2022-11

3. Exploration of Ultralarge Compound Collections for Drug Discovery;Journal of Chemical Information and Modeling;2022-04-14